NewsRoom Articles - BioMedWire (BMW)

MondayJul 20, 2026 9:45 am

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy Investopedia lists the lack of reliable…

FridayJul 17, 2026 10:00 am

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Scientists have been racing to establish why some patients respond to cancer immunotherapy while others do not. A recent study has linked metabolites produced by certain bacteria in the gut to improved responses to cancer immunotherapy in patients. The study, whose findings were published in the journal Cell Reports Medicine, was conducted by a large team led by researchers at the University of Nebraska and Cedars-Sinai, alongside collaborators based at other academic institutions. Ramer-Tait from the University of Nebraska led the research effort. Previous research has variously linked gut microbiota to improved responses to cancer immunotherapy. However, no study had pinpointed a specific microbe or microbial metabolite linked to immunotherapy response improvements…

ThursdayJul 16, 2026 10:00 am

Initiatives to Erase Medical Debt Gain Traction Across the US

According to KFF research conducted in 2022, about 100 million individuals in the U.S. are saddled with medical debt. This debt often makes it nearly impossible for them to afford other necessities of life, including additional medical care. As lawmakers on Capitol Hill drag their feet on enacting definitive remedies to the escalating healthcare costs, state governments and philanthropists are taking action to wipe medical debt away. Undue Medical Debt is a nonprofit organization that is focused on mobilizing donations and using the funds it gets to wipe away the crippling medical debt that low-income earners in the U.S. face. The nonprofit has come up with a model through which…

WednesdayJul 15, 2026 9:00 am

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Earth Science Tech has positioned itself within the rapidly evolving telehealth industry, through its investments into subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc. The company is capitalizing on the surging demand and clinical effectiveness of peptide therapies, an industry expected to hit $249 billion by 2033. ETST’s success has been built on its proprietary tech and IT infrastructure, a significant competitive edge, and continues to push innovative tech development and expand vertical integration. Earth Science Tech (OTC: ETST), a strategic holding company building value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services,…

TuesdayJul 14, 2026 10:00 am

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Not many people know that respiratory infections have been strongly linked to cardiovascular disease events, and this knowledge gap is leading to missed opportunities to use readily accessible vaccines to limit the severity and challenges arising from cardiovascular disease. Professor Colin Russell, based at the School of Medicine at Amsterdam University, explains why it is important to understand the role that respiratory infections play in cardiovascular disease. He points out that fragmented data on immunization coverage is a leading barrier that prevents vaccination against respiratory infections from making a bigger contribution in the fight against cardiovascular disease. Prof. Russell points…

TuesdayJul 14, 2026 9:45 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks. VERAXA's Boolean "AND-gated" BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because…

FridayJul 10, 2026 10:00 am

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors. In a study that was published in the Nature journal, the scientists described their small trial that involved 33 patients diagnosed with high-grade astrocytomas. These tumors usually recur and progress to a level that…

ThursdayJul 09, 2026 10:00 am

Understanding Why Treatment Resistance Exists in Many Cancers

One of the biggest challenges that the medical community faces in fighting cancer is the treatment resistance phenomenon. Treatment resistance results in poor prognosis for patients due to the inability of available treatments to deliver meaningful beneficial changes in cancer progression. We discuss some of the mechanisms that have been studied as scientists search for a solution to treatment resistance in cancer patients. For starters, it has now become clear that treatment resistance can be broadly categorized into two distinct groups. The first is primary/innate/intrinsic resistance, in which from the get-go, a patient doesn’t respond to the available cancer treatments…

ThursdayJul 09, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform

Oncotelic has launched an AI-powered GMP manufacturing services platform that integrates its PDAOAI(TM) architecture, digital batch records, and intelligent robotics built with partner TechForce Robotics The platform targets emerging biotechs, CDMOs, cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house The same AI-GMP capabilities already run inside Oncotelic's SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line For emerging biotechnology companies, the road from promising science to clinical execution often breaks down in the same place: manufacturing. Discovery can begin in a university lab, a…

WednesdayJul 08, 2026 10:30 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing. VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Initiatives to Erase Medical Debt Gain Traction Across the US

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

Understanding Why Treatment Resistance Exists in Many Cancers

Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform

VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search